» Articles » PMID: 30485204

Intravenous Infusion of Mesenchymal Stem Cells for Protection Against Brainstem Infarction in a Persistent Basilar Artery Occlusion Model in the Adult Rat

Overview
Journal J Neurosurg
Specialty Neurosurgery
Date 2018 Nov 29
PMID 30485204
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Morbidity and mortality in patients with posterior circulation stroke remains an issue despite advances in acute stroke therapies. The intravenous infusion of mesenchymal stem cells (MSCs) elicits therapeutic efficacy in experimental supratentorial stroke models. However, since there are few reliable animal models of ischemia in the posterior circulation, the therapeutic approach with intravenous MSC infusion has not been tested. The objective of this study was to test the hypothesis that intravenously infused MSCs provide functional recovery in a newly developed model of brainstem infarction in rats.

Methods: Basilar artery (BA) occlusion (BAO) was established in rats by selectively ligating 4 points of the proximal BA with 10-0 nylon monofilament suture. The intravenous infusion of MSCs was performed 1 day after BAO induction. MRI and histological examinations were performed to assess ischemic lesion volume, while multiple behavioral tests were performed to evaluate functional recovery.

Results: The MSC-treated group exhibited a greater reduction in ischemic lesion volume, while behavioral testing indicated that the MSC-infused group had greater improvement than the vehicle group 28 days after the MSC infusion. Accumulated infused MSCs were observed in the ischemic brainstem lesion.

Conclusions: Infused MSCs may provide neuroprotection to facilitate functional outcomes and reduce ischemic lesion volume as evaluated in a newly developed rat model of persistent BAO.

Citing Articles

Therapeutic potential of mesenchymal stem cells for cerebral small vessel disease.

Chen D, Huang J, Su S, Chen Q, Wu B Regen Ther. 2024; 25:377-386.

PMID: 38414558 PMC: 10899004. DOI: 10.1016/j.reth.2023.11.002.


Intravenous infusion of bone marrow-derived mesenchymal stem cells improves tissue perfusion in a rat hindlimb ischemia model.

Maeda S, Kawamura T, Sasaki M, Shimamura K, Shibuya T, Harada A Sci Rep. 2022; 12(1):16986.

PMID: 36216855 PMC: 9551049. DOI: 10.1038/s41598-022-18485-1.


Intravenous Infusion of Autoserum-Expanded Autologous Mesenchymal Stem Cells in Patients With Chronic Brain Injury: Protocol for a Phase 2 Trial.

Oka S, Yamaki T, Sasaki M, Ukai R, Takemura M, Yokoyama T JMIR Res Protoc. 2022; 11(7):e37898.

PMID: 35793128 PMC: 9301565. DOI: 10.2196/37898.


Prolonged lifespan in a spontaneously hypertensive rat (stroke prone) model following intravenous infusion of mesenchymal stem cells.

Nakazaki M, Oka S, Sasaki M, Kataoka-Sasaki Y, Nagahama H, Hashi K Heliyon. 2021; 6(12):e05833.

PMID: 33392407 PMC: 7773587. DOI: 10.1016/j.heliyon.2020.e05833.


Safety and Efficacy of Intraventricular Delivery of Bone Marrow-Derived Mesenchymal Stem Cells in Hemorrhagic Stroke Model.

Huang P, Freeman W, Edenfield B, Brott T, Meschia J, Zubair A Sci Rep. 2019; 9(1):5674.

PMID: 30952961 PMC: 6450980. DOI: 10.1038/s41598-019-42182-1.